Table 6. Serious Medical Events between the Year 2 and the Follow-up Study Visit by Dosing Regimen Assigned in the Clinical Trial

	Dosing Regimen Assigned in the Clinical Trial						
	2 Years Monthly (N=284)		Switched (N=260)		2 Years As Needed (N=546)		
Serious Medical Event	**n**	**(%)**	**n**	**(%)**	**n**	**(%)**	**P[§]**
Death-all causes	58	(20.4)	47	(18.1)	98	(17.9)	0.66
Arteriothrombotic events	19	(6.7)	13	(5.0)	34	(6.2)	0.71
Venous thrombotic events	2	(0.7)	1	(0.4)	6	(1.1)	0.69
Hypertension	9	(3.2)	9	(3.5)	9	(1.6)	0.18
One or more serious medical events	141	(49.6)	138	(53.1)	254	(46.5)	0.21
Previously associated with anti-VEGF treatment[‡]	51	(18.0)	37	(14.2)	89	(16.3)	0.50
MedDRA[†] system organ class**							
Cardiac disorders	34	(12.0)	25	(9.6)	61	(11.2)	0.68
Infections	19	(6.7)	21	(8.1)	35	(6.4)	0.67
Nervous system disorders	21	(7.4)	21	(8.1)	40	(7.3)	0.92
Injury and procedural complications	10	(3.5)	21	(8.1)	26	(4.8)	0.054
Neoplasms benign and malignant	30	(10.6)	23	(8.8)	44	(8.1)	0.49
Gastrointestinal disorders	11	(3.9)	10	(3.8)	15	(2.7)	0.53

[§]Fisher's exact test

[‡] Arteriothrombotic events, systemic hemorrhage, congestive heart failure, venous thrombotic events, hypertension, vascular death

[†]Medical Dictionary for Regulatory Activities